| Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer: the MYSTIC phase 3 randomized clinical trial NA Rizvi, BC Cho, N Reinmuth, KH Lee, A Luft, MJ Ahn, ... JAMA oncology 6 (5), 661-674, 2020 | 506 | 2020 |
| Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled … M Maio, A Scherpereel, L Calabrò, J Aerts, SC Perez, A Bearz, ... The Lancet Oncology 18 (9), 1261-1273, 2017 | 431 | 2017 |
| Vandetanib versus gefitinib in patients with advanced non–small-cell lung cancer: results from a two-part, double-blind, randomized phase II study RB Natale, D Bodkin, R Govindan, BG Sleckman, NA Rizvi, A Capó, ... Journal of Clinical Oncology 27 (15), 2523-2529, 2009 | 212 | 2009 |
| A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or … E Van Cutsem, YJ Bang, W Mansoor, RD Petty, Y Chao, D Cunningham, ... Annals of Oncology 28 (6), 1316-1324, 2017 | 161 | 2017 |
| ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial RB Natale, D Bodkin, R Govindan, B Sleckman, N Rizvi, A Capo, ... Journal of Clinical Oncology 24 (18_suppl), 7000-7000, 2006 | 149 | 2006 |
| Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia B Löwenberg, P Muus, G Ossenkoppele, P Rousselot, JY Cahn, N Ifrah, ... Blood, The Journal of the American Society of Hematology 118 (23), 6030-6036, 2011 | 137 | 2011 |
| Clinical evaluation of AZD1152, an iv inhibitor of Aurora B kinase, in patients with solid malignant tumors DS Boss, PO Witteveen, J Van Der Sar, MP Lolkema, EE Voest, ... Annals of Oncology 22 (2), 431-437, 2011 | 118 | 2011 |
| Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low‐dose cytosine arabinoside in elderly patients with acute myeloid … HM Kantarjian, G Martinelli, EJ Jabbour, A Quintás‐Cardama, K Ando, ... Cancer 119 (14), 2611-2619, 2013 | 113 | 2013 |
| Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC NA Rizvi, BC Cho, N Reinmuth, KH Lee, MJ Ahn, A Luft, ... Annals of Oncology 29, x40-x41, 2018 | 112 | 2018 |
| ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer D Planchard, N Reinmuth, S Orlov, JR Fischer, S Sugawara, S Mandziuk, ... Annals of Oncology 31 (5), 609-618, 2020 | 111 | 2020 |
| Identification of a basic hybrid glutathione S-transferase from human liver. Glutathione S-transferase δ is composed of two distinct subunits (B1 and B2) PK Stockman, GJ Beckett, JD Hayes Biochemical Journal 227 (2), 457-465, 1985 | 95 | 1985 |
| Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors GK Schwartz, RD Carvajal, R Midgley, SJ Rodig, PK Stockman, O Ataman, ... Investigational new drugs 31, 370-380, 2013 | 88 | 2013 |
| Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia M Dennis, M Davies, S Oliver, R D’Souza, L Pike, P Stockman Cancer chemotherapy and pharmacology 70, 461-469, 2012 | 72 | 2012 |
| Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. F Andre, M Ranson, E Dean, A Varga, R Van der Noll, PK Stockman, ... Cancer research 73 (8_Supplement), LB-145-LB-145, 2013 | 71 | 2013 |
| Variations in the glutathione S-transferase subunits expressed in human livers AJ Hussey, PK Stockman, GJ Beckett, JD Hayes Biochimica et Biophysica Acta (BBA)-Protein Structure and Molecular …, 1986 | 70 | 1986 |
| Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML HM Kantarjian, MA Sekeres, V Ribrag, P Rousselot, G Garcia-Manero, ... Clinical Lymphoma Myeloma and Leukemia 13 (5), 559-567, 2013 | 69 | 2013 |
| Characterization of the basic glutathione S-transferase B1 and B2 subunits from human liver PK Stockman, LI McLELLAN, JD Hayes Biochemical Journal 244 (1), 55-61, 1987 | 69 | 1987 |
| A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor … YJ Bang, E Van Cutsem, W Mansoor, RD Petty, Y Chao, D Cunningham, ... Journal of Clinical Oncology 33 (15_suppl), 4014-4014, 2015 | 67 | 2015 |
| ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients ADJ Pearson, C Rossig, G Lesa, SJ Diede, S Weiner, J Anderson, J Gray, ... European Journal of Cancer 127, 52-66, 2020 | 57 | 2020 |
| Tremelimumab as second-or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study. HL Kindler, A Scherpereel, L Calabrò, J Aerts, S Cedres Perez, A Bearz, ... Journal of Clinical Oncology 34 (15_suppl), 8502-8502, 2016 | 56 | 2016 |
